Diadem touts studies on Alzheimer's detection

2020 03 31 23 03 5810 Brain Dementia Leaves 400

Diadem is touting findings from three studies that point to the potential effectiveness of its AlzoSure blood-based biomarker assay to identify individuals with a high risk for developing Alzheimer's disease (AD).

AlzoSure is a plasma-based biomarker designed to predict the likelihood that a patient will develop Alzheimer's. Using patented technology, the assay employs an antibody that binds to a conformational variant of the p53 protein, U-p53AZ, which is a protein that plays a key role in AD progression.

Diadem shared the results of three studies highlighting how researchers could use U-p53AZ and AlzoSure to predict AD onset years before symptoms appear.

In the first study, published on December 3 in Alzheimer's Research & Therapy, researchers described how p53 dysregulation may exacerbate AD pathology. The authors concluded that p53 does have the potential to serve as a biomarker for early detection of AD.

In the second publication, published December 26 in Journal of Personalized Medicine, researchers specifically assessed Diadem's blood-based prognostic test in a longitudinal study of 375 patients. The authors confirmed Diadem's antibody can reliably recognize the U-p53 conformation variant and said U-p53AZ levels in blood showed high accuracy for discriminating between people with mild cognitive impairment who did and did not develop AD.

The third and final publication was released as a preprint on January 26 and included results from a longitudinal study on AlzoSure. The authors demonstrated that U-p53AZ predicted progression from mild cognitive impairment to AD at least 36 months before alternative diagnosis. In one patient, U-p53AZ levels predicted AD advancement at least six years before the patient developed AD symptoms.

Page 1 of 4
Next Page